| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 17.35▲ | 17.44▼ | 17.49▼ | 17.50▼ | 18.26▼ |
| MA10 | 17.33▲ | 17.54▼ | 17.63▼ | 17.49▼ | 19.33▼ |
| MA20 | 17.41▼ | 17.68▼ | 17.74▼ | 18.28▼ | 19.48▼ |
| MA50 | 17.60▼ | 17.62▼ | 17.41▼ | 19.78▼ | 20.97▼ |
| MA100 | 17.71▼ | 17.45▼ | 17.95▼ | 19.42▼ | N/A |
| MA200 | 17.54▼ | 18.08▼ | 18.74▼ | 18.11▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | -0.055▼ | -0.065▼ | 0.012▲ | -0.108▼ |
| RSI | 44.392▼ | 40.726▼ | 43.495▼ | 41.502▼ | 44.900▼ |
| STOCH | 50.428 | 17.207▼ | 26.211 | 25.963 | 19.963▼ |
| WILL %R | -67.857 | -83.125▼ | -85.789▼ | -85.823▼ | -70.953 |
| CCI | -47.419 | -115.186▼ | -144.449▼ | -43.793 | -112.682▼ |
| MA | $NGNE Price Crossed Below MA(7) | Set Alert |
|
Friday, September 05, 2025 09:01 AM
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, ...
|
|
Thursday, September 04, 2025 07:50 AM
The U.S. Food and Drug Administration on Thursday introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 17.65 | 18.06 | 17.18 | 17.33 | 128,360 |
| 29/09/25 | 17.86 | 18.15 | 17.51 | 17.71 | 138,324 |
| 26/09/25 | 17.43 | 18.13 | 17.24 | 17.82 | 117,549 |
| 25/09/25 | 17.00 | 17.45 | 16.85 | 17.405 | 127,774 |
| 24/09/25 | 16.94 | 17.525 | 16.94 | 17.25 | 128,315 |
| 23/09/25 | 17.14 | 17.51 | 16.77 | 16.85 | 152,097 |
| 22/09/25 | 17.25 | 17.93 | 16.95 | 16.98 | 221,381 |
| 19/09/25 | 18.68 | 18.68 | 17.00 | 17.20 | 215,471 |
| 18/09/25 | 18.03 | 18.94 | 17.6355 | 18.68 | 131,618 |
| 17/09/25 | 17.58 | 18.395 | 17.547 | 17.71 | 111,407 |
|
|
||||
|
|
||||
|
|